Estrogen receptors (ERs) are a group of receptor proteins that are activated by the hormone estrogen. Once activated by estrogen, the ER can translocate into the nucleus and bind with DNA to regulate the activity of different genes. About 80% of all breast cancers are "ER-positive" which is one of the two types of hormonereceptor- positive breast cancer. Tumors that are ERpositive are much more likely to respond to hormone therapy than tumors that are ER/PR (estrogen/progesterone) negative. The presence of ER in breast tumors indicates an increased likelihood of response to anti-estrogen therapy. In the present study, we have developed and characterized a monoclonal antibody against Estrogen receptors. The level of expression of ER is examined in human breast cancer tissues by using the developed anti-ER monoclonal antibody in immunohistochemistry. It was found that this monoclonal antibody is specific to estrogen receptors and shows minimal cross-reaction with other members of the family which were validated by ELISA, Western blotting and Immuno-histochemistry. It strongly strains nuclei of epithelial cells in breast carcinomas and so the developed monoclonal antibody can be used in the diagnosis of positive breast cancer.
Read full abstract